A translational bridge to cancer immunotherapy: Exploiting costimulation and target antigens for active and passive T cell immunotherapy

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 341-355

  Vonderheide, Robert H ^a,b,c   June, Carl H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive therapy; Costimulation; Telomerase; Vaccine

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; ENZYME; PEPTIDE DERIVATIVE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; GENETIC ENGINEERING; HISTOLOGY; HUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TECHNOLOGY;

ANIMALS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 0141456259     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:341     Document Type: Review

References (73)

1. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al.: Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-578.
2. Heslop HE, Rooney CM: Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997;157:217-222.
3. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
4. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
5. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Eng J Med 1994;330:100-106.
6. Alyea E: Adoptive immunotherapy:insights from donor lymphocyte infusions. Transfusion 2000;40:393-395.
7. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever M: A T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. Journal of Immunology 1991;146:4414-4420.
8. Katsanis E, Xu Z, Anderson PM, Dancisak BB, Bausero MA, Weisdorf DJ, et al.: Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplant 1994;14:563-572.
9. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH: Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-5930.
10. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, et al.: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-1943.
11. Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984;53:896-905.
12. Curd BD, Ochoa, AC, Powers GC, Kopp WC, Alvord WG, Janik JE, et al.: Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol 1998;16:2752-2760.
13. Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, et al.: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-448.
14. Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, et al.: Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53.
15. Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, et al.: Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 1998;4:852-856.
16. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, et al.: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999;5:34-41.
17. Tan R, Xu X, Ogg GS, Hansasuta P, Dong T, Rostron T, et al.: Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999;93:1506-1510.
18. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
19. Deeths MJ, Kedl RM, Mescher MF: CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999;163:102-110.
20. Laux I, Khoshnan A, Tindell C, Bae D, Zhu X, June CH, et al.: Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol 2000;96:187-197.
21. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993;150:771-781.
22. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS: Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995;155:3360-3367.
23. Hurtado JC, Kim YJ, and Kwon BS: Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997;158:2600-2609.
24. Shuford WW, Klussman K, Tritchlet DD, Loo DT, Chalupny J, Siadak AW, et al.: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55.
25. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999;162:5037-5040.
26. Tan JT, Whitmire JK, Murali-Krishna K, Ahmed R, Altman JD, Mittler RS, et al.: 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000;164:2320-2325.
27. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE., et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685.
28. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L: Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998;28:1116-1121.
29. DeBenedette MA, Shahinian A, Mak TW, Watts TH: Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997;158:551-559.
30. Guinn, BA, DeBenedette MA, Watts TH, Berinstein NL: 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-5010.
31. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, et al.: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20:143-148.
32. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-373.
33. Yee C, Riddell SR, Greenberg PD: In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001;13:141-146.
34. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
35. Fefer A: Adoptive chemo-immunotherapy of a Moloney lymphoma. Int J Cancer 1971;8:364-373.
36. Wong RA, Alexander RB, Puri RK, Rosenberg SA: In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunother 1991;10:120-130.
37. De Boer RJ, Hogeweg P, Dullens HF, De Weger RA, Den Otter W: Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. J Immunol 1985;134:2748-2758.
38. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in anti-tumor immunity. Curr Opin Immunol 1998;10:588-594.
39. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
40. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, et al.: Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-787.
41. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
42. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
43. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med 1996;2:52-58.
44. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-473.
45. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.
46. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Euro J Immunol 1994;24:605-610.
47. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995;1:1297-1302.
48. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
49. Mayordomo JI, Loftus DJ, Sakamoto H, Decesare CM, Appasamy PM, Lotze MT, et al.: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
50. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
51. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-180.
52. Gilboa E: The makings of a tumor rejection antigen. Immunity 1999;11:263-270.
53. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, et al.: Structure of the gene of turn- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989;58:293-303.
54. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA: Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-1354.
55. Schultze JL, Vonderheide RH: From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-523.
56. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-679.
57. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-679.
58. Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 2000;18:2626-2634.
59. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-468.
60. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al.: Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-1170.
61. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001;7:3343-3348.
62. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S: Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001;97:2903-2907.
63. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY: Identification of FILA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 2002;2:2600-2605.
64. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, et al.: Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-beating patients and healthy individuals. Cancer Res 2001;61:8366-8370.
65. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, et al.: Induction of cytotoxic T lymphocyte responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-1017.
66. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, et al.: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001;166:2953-2960.
67. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388-3393.
68. Harle-Bachor C, Boukamp P: Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996;93:6476-6481.
69. Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, et al.: Telomerase activity in normal human epithelial cells. Oncogene 1996;13:433-439.
70. Norrback KF, Roos G: Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997;33:774-780.
71. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, et al.: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998;19:182-186.
72. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97:4796-4801.
73. Vonderheide RH, Domchek SM, Hahn WC, George DJ, Stephans KF, Schultze JL, Nadler LM: Vaccination of cancer patients against telomerase: a phase I study using peptide-pulsed dendritic cells. Blood 2001;98S:508a.